Agilus Diagnostics announces 3-Day turnaround for Myeloid Malignancy Genomic Testing

Agilus Diagnostics, India’s diagnostic network, has introduced a three-day turnaround time (TAT) for test results in myeloid malignancies. This development comes as the genomic testing market in India continues to grow, driven by advancements in technology and increasing demand for personalised medicine. The market, valued at approximately USD 150 million, is projected to expand at a compound annual growth rate (CAGR) of over 15% in the next five years.

Genomic testing is changing cancer diagnostics by providing information on genetic profiles. This helps clinicians identify mutations, adjust treatment plans, and choose therapies that may offer higher efficacy. Genomic testing enables early detection and targeted intervention, which may improve disease management.

The Myeloid Genomics Testing covers 79 genes linked to inherited risks and detects mutations and fusions, allowing for treatment recommendations for conditions such as Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN). The reports are reviewed by pathologists and include risk assessment tools and therapy suggestions based on current standards.

“Our 3-day genomic testing initiative for myeloid malignancies addresses one of the biggest challenges in precision oncology — Time. With this breakthrough, Agilus Diagnostics is not only setting a new industry standard but also transforming patient care by enabling faster diagnoses and treatment,” said Dr. Anand K, Managing Director & CEO of Agilus Diagnostics.

Labs in the genomic testing field typically take two to three weeks to deliver results for myeloid malignancies, which can delay critical decisions. Agilus Diagnostics’ faster testing approach reduces the time required for diagnosis and lessens hospital visits.

Agilus Diagnostics ensures that each report is individualised, with molecular pathologists interpreting the results. This provides clinicians with insights that support timely and effective decisions in patient management.

“With our advanced genomic testing capabilities, we aim to provide clinicians with the tools they need to make timely, informed decisions. This not only improves outcomes but also sets a new benchmark for the healthcare industry in India,” added Dr. Anand K.

Agilus Diagnostics continues to offer genomic testing services that meet international standards, providing Indian patients with access to diagnostic services for better disease management.